Boyd Street Ventures has announced an investment in biotech company Cadenza Bio. The company focuses on developing small molecules for demyelinating and inflammatory diseases, with a specific focus on multiple sclerosis (MS). Cadenza Bio aims to halt the progression of MS, restore function, and improve the quality of life for patients. The company holds an exclusive license to technology developed through a research collaboration between Dr. John Katzenellenbogen of the University of Illinois Urbana-Champaign and Dr. Seema Tiwari-Woodruff of the University of California, Riverside. Boyd Street Ventures is impressed with the potential of Cadenza Bio and believes that their participation will play a meaningful role in the company’s growth and development.
Boyd Street Ventures backs game-changer, Cadenza Bio’s biotech breakthrough!
Latest from Blog
Birdnest Soars with Pre-Series A Funding from Beltone Venture
Summary of Article: Proptech startup Birdnest secures pre-Series A funding led by Beltone Venture Capital TLDR: Egyptian proptech startup Birdnest secures pre-Series A funding led by Beltone Venture Capital Round also included
Navigating the highs and lows of European investment landscape
TLDR: TechCrunch is part of the Yahoo family of brands Cookies are used on their sites and apps for various purposes TechCrunch, as part of the Yahoo family of brands, uses Cookies
Venture Capital Boost: Blockchain Firms Secure $258m in One Week
TLDR: During the week of May 19 to May 25, blockchain startups collectively raised over $258 million, spearheaded by decentralized social protocol Farcaster’s $150 million series A round. The funding rounds included
The Ultimate Guide to Venture Capital Funding: Your Complete Overview
TLDR: – Venture capital funding is a significant catalyst for innovation and growth for startups. – Companies typically go through different types of funding rounds, with VCs interested in injecting cash in
Shorooq Partners Announces $100M Venture Debt Fund, First Close
TLDR: Shorooq Partners has launched a new $100 million venture debt fund and hit its first close. The fund will focus on investing in Series A+ companies in various sectors with an